I think the recent KLAS rating has given Mach7 a bit of a kick in the pants. That the company has a wide ranging set of initiatives to improve is testament to that, according to Mike Lampron on the Quarterly Report call.
I am looking forward to a few more large contract wins including the VA extension. I am also looking forward to seeing positive cashflow being a consistent feature of the business and hopefully get it off the issues list as far as investors are concerned.
I initially invested in Mach7 because it is a business that is in business to help the medical profession save costs and in the medical world at the moment that is a very valuable trait, so I reckon my thesis is still in tact I just hope Mike Lampron can execute as well as I had hoped.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-12
Add M7T (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
65.0¢ |
Change
-0.010(1.52%) |
Mkt cap ! $156.8M | |||
| Open | High | Low | Value | Volume |
| 64.5¢ | 65.5¢ | 62.5¢ | $76.3K | 119.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5000 | 63.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 65.5¢ | 44381 | 1 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
65.0¢ |
Change
-0.010 ( 0.76 %) |
||||
| Open | High | Low | Volume | ||
| 65.5¢ | 66.0¢ | 62.0¢ | 53816 | ||
| Last updated 15.59pm 14/06/2024 ? | |||||
| M7T (ASX) Chart |